

Tilburg University

Bloedspiegelbepalingen van antipsychotica bij patienten in twee tbs-klinieken

de Blécourt, C. V.; Oei, T. I.

Published in:
[n.n.]

Publication date:
2009

[Link to publication in Tilburg University Research Portal](#)

Citation for published version (APA):
de Blécourt, C. V., & Oei, T. I. (2009). Bloedspiegelbepalingen van antipsychotica bij patienten in twee tbs-klinieken. In [n.n.] (Vol. 51, pp. S232-S233). (Tijdschrift voor Psychiatrie; Vol. 51, No. 1). Unknown Publisher.


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



forensisch psychiatrisch centrum
OLDENKOTTE



Bloedspiegelbepalingen van antipsychotica bij patiënten in twee TBS-klinieken

CV de Blécourt, (FPC Oldenkotte)
TI Oei, (Universiteit van Tilburg)



Agenda

- **Introduction**
- **Previous experiences in General Psychiatry (1984 – 2006)**
- **Actual experiences in Forensic Psychiatry**
- **Discussion**
- **Conclusions**
- **Research proposal**

Patient 1

Male, age 36

Zuclopentixol depot, 300 mg / 2 weeks

(Maintenance dose: 200 – 600 mg / 2 - 4 weeks)

Supposed therapeutical range: 10 – 50

Value: 6

Patient 2

Male, age 38

Zuclopentixol depot, 1000 mg / 3 weeks

(Maintenance dose: 200 – 600 mg / 2 - 4 weeks)

Supposed therapeutical range: 10 – 50

Value: 13

Patient 3

Male, age 63

Zuclopentixol depot, 200 mg / 2 weeks

(Maintenance dose: 200 – 600 mg / 2 - 4 weeks)

Supposed therapeutical range: 10 – 50

Value: 8

Patient 4

Male, age 41

Zuclopentixol depot, 350 mg / 2 weeks

(Maintenance dose: 200 – 600 mg / 2 - 4 weeks)

Supposed therapeutical range: 10 – 50

Value: 11

Summary

Nr	Medication	Depot mg	Weeks	Range	Value
3	Zuclopent.	200	2	10-50	8
1	Zuclopent.	300	2	10-50	6
4	Zuclopent.	350	2	10-50	11
2	Zuclopent.	1000	3	10-50	13

Patient 4

Male, age 41

Risperidon depot, 50 mg / 2 weeks

(Maintenance dose: 25 mg / 2 weeks if oral dose is 4 mg / day)

Supposed therapeutical range: 10 – 90

Value: 33

Patient 5

Male, age 41

Risperidon depot, 50 mg / 2 weeks

(Maintenance dose: 25 mg / 2 weeks if oral dose is 4 mg / day)

Supposed therapeutical range: 10 – 90

Value: 21

Patient 6

Male, age 27

Risperidon depot, 50 mg / 2 weeks

(Maintenance dose: 25 mg / 2 weeks if oral dose is 4 mg / day)

Supposed therapeutical range: 10 – 90

Value: 20

Patient 7

Male, age 43

Risperidon depot, 62,5 mg / 2 weeks

(Maintenance dose: 25 mg / 2 weeks if oral dose is 4 mg / day)

Supposed therapeutical range: 10 – 90

Value: 36

Summary

Nr	Medication	Depot mg	Weeks	Range	Value
5	Risperidon	50	2	10-90	21
6	Risperidon	50	2	10-90	20
4	Risperidon	50	2	10-90	33
7	Risperidon	62.5	2	10-90	36

Patient 8

Male, age 24

Quetiapine, 900 mg / day

(Maintenance dose: 300 - 450 mg / day)

Supposed therapeutical range (at the time): 50 - 750

Value: 38

Patient 9

Male, age 46

Quetiapine, 800 mg / day

(Maintenance dose: 300 - 450 mg / day)

Supposed therapeutical range (at the time): 50 - 750

Value: 31

Patient 9

Male, age 46

Quetiapine, 1000 mg / day

(Maintenance dose: 300 - 450 mg / day)

Supposed therapeutical range (at the time): 50 - 750

Value: 57

Patient 10

Male, age 38

Quetiapine, 1000 mg / day

(Maintenance dose: 300 - 450 mg / day)

Supposed therapeutical range (at the time): 50 - 750

Value: 110

Summary

Nr	Medication	Depot mg	Day	Range	Value
9	Quetiapine	800		50-750	31
8	Quetiapine	900		50-750	38
9	Quetiapine	1000		50-750	57
10	Quetiapine	1000		50-750	110
16	Quetiapine	1000		50-400	37

Patient 11

Male, age 41

Olanzapine, 20 mg / day

(Maintenance dose: 5 - 20 mg / day)

Supposed therapeutical range: 20 - 50

Value: 13

Patient 12

Male, age 25

Risperidon, 9 mg / day

(Maintenance dose: 4 - 8 mg / day)

Supposed therapeutical range: 10 - 90

Value: 83

Patient 13

Male, age 26

Aripiprazole, 15 mg / day

(Maintenance dose: 15 mg / day)

Supposed therapeutical range: 100 - 500

Value: 98

Patient 14

Male, age 30

Aripiprazole , 15 mg / day

(Maintenance dose: 15 mg / day)

Supposed therapeutical range: 100 - 500

Value: 187

Patient 15

Female, age 37 (outdoor patient)

Quetiapine , 1000 mg / day

(Maintenance dose: 300 - 450 mg / day)

Supposed therapeutical range: 50 - 400

Value: 37

Patient 16

Female, age 28

Haloperidol, 5 mg / day

(Maintenance dose: 4 - 10 mg / day)

Supposed therapeutical range: 5 - 15

Value: 1

Patient 16

Female, age 28

Haloperidol, 15 mg / day

(Maintenance dose: 4 - 10 mg / day)

Supposed therapeutical range: 5 - 15

Value: 6,9

Patient 17

Male, age 29

Haloperidol, 40 mg / day

(Maintenance dose: 4 - 10 mg / day)

Supposed therapeutical range: 5 - 15

Value: 13

Patient 18

Male, age 34

Flupentixol depot, 30 mg / 3 weeks

(Maintenance dose: 20 - 40 mg / 2 - 4 weeks)

Supposed therapeutical range: 1 - 20

Value: 2,6

Patient 19

Female, age 29

Flupentixol depot, 40 mg / 2 weeks

(Maintenance dose: 20 - 40 mg / 2 - 4 weeks)

Supposed therapeutical range: 1 - 20

Value: 2,0

Patient 20

Male, age 33

Haloperidol depot, 100 mg / 4 weeks

(Maintenance dose: 50 - 150 mg / 4 weeks)

Value: not measurable

Discussion

- Selection bias
- Informed consent essential
- Plasma monitoring favours doctor patient relationship

Conclusions 1

Ultra rapid metabolism is excluded pharmacogenetically.

Metabolism is on the rapid side of the Gaussian distribution.

High incidence of side effects, especially of akathisia.

“ Two way knock-out punch to Therapy”.

Conclusions 2

Take caution in prescribing Aripiprazole in violent patients

Risperidon consta in fixed dose does not yield reproducible plasma values in all patients

Conclusions 3

Results for Quetiapine might stimulate research to genduplication of 2C19, or a variant mutation associated with increased metabolic activity such as the 2C19*17 mutation (omeprazol) (TOUW et al.,2008)

Conclusions 4

- Rapid metabolism
- Acathisia
- Violent behaviour

If this Triad would be recognized already in the General Mental Hospital:

Might Prevention then be possible?

Research proposal

Form an international group to focuss on this subject.

E-mail adress:

c.blecourt@dji.minjus.nl